Next-Generation HIF-2α Inhibitor Demonstrates Potential in Translational Clinical Trial for Kidney Cancer
In a groundbreaking advancement for kidney cancer therapeutics, researchers at the Dana-Farber Cancer Institute have pioneered the first-in-patient clinical trial ...
